Basic Information
| Drug ID | DDPD00586 |
|
| Drug Name | Diclofenac | |
| Molecular Weight | 296.149 | |
| Molecular Formula | C14H11Cl2NO2 | |
| CAS Number | 15307-86-5 | |
| SMILES | OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl | |
| External Links | ||
| DRUGBANK | DB00586 | |
| T3DB | T3D4729 | |
| PubChem Compound | 3033 | |
| PDR | 1070 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 4.51 | - | 4.51 | - | AVDEEF,A (1997) |
| Melting Point | 284.0 | ℃ | 283-285 | ℃ | DRUGBANK |
| Water Solubility | 2.37 | mg/L | 2.37 | mg/L | FINI,A ET AL. 1986) |
| pKa | 4.15 | - | 4.15 | - | SANGSTER (1994) |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | 100 | % | PO, oral; | DRUGBANK | |
| Bioavailability | 60.0 | % | 60 | % | PO, oral; | DRUGBANK | Bioavailability | 54.0 | % | 54±2 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 2000.0 | ng/ml | 2.0(1.4-3.0) | mcg/ml | Tablet, PO, oral; extended release formulation; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | C Max | 420.0 | ng/ml | 0.42±0.17 | mcg/ml | Tablet, PO, oral; Sustained Release formulation; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| T Max | 0.42 | h | 0.17-0.67 | h | Capsule, PO, Oral; | DRUGBANK | T Max | 1.8 | h | 1.5-2 | h | Tablet, PO, oral; | DRUGBANK | T Max | 7.3 | h | 2.5-12 | h | PO, oral; food; | food ↑ ; | DRUGBANK | T Max | 2.5 | h | 2.5(1.0-4.5) | h | Tablet, PO, oral; extended release formulation; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | T Max | 5.3 | h | 5.3±1.5 | h | Tablet, PO, oral; Sustained Release formulation; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| Clearance | 16.0 | L/h | 16.0 | L/h | Plasma clearance; | DRUGBANK | Clearance | 0.25 | L/h/kg | 4.2±0.9 | ml/min/kg | Urinary excretion; Bile excretion; | Elderly → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ; | The Pharmacological Basis of Therapeutics | Clearance | 0.21 | L/h/kg | 3.5 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 0.15 | L/kg | 0.1-0.2 | L/kg | Total volume of distribution; | DRUGBANK | Volume of Distribution | 0.17 | L/kg | 0.17±0.11 | L/kg | rheumatoid arthritis ↑ ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.22 | L/kg | 0.22 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 2.0 | h | ~2 | h | terminal half-life; | DRUGBANK | Half-life | 29.4 | h | 25.8-33 | h | Metabolite; | DRUGBANK | Half-life | 1.1 | h | 1.1±0.2 | h | rheumatoid arthritis → ; | The Pharmacological Basis of Therapeutics | Half-life | 1.4 | h | 1.4 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 390.0 | mg/kg | 390.0 | mg/kg | PO, oral; mouse; | T3DB | |
| Eliminate Route | 65.0 | % | 60-70 | % | Urinary excretion; | DRUGBANK | Eliminate Route | 30.0 | % | 30 | % | Faeces excretion; | DRUGBANK | Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 99.7 | % | >99.7 | % | DRUGBANK | Protein Binding | 99.5 | % | >99.5 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 2.0 | patches/day | 2 | patches/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
| Max dose for adolescents | 2.0 | patches/day | 2 | patches/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 150.0 | mg/day | 150 | mg/day | intravenous injection, IV | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 200.0 | mg/day | 200 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 150.0 | mg/day | 150 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 125.0 | mg/day | 125 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 32000.0 | mg/day | 32 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 16000.0 | mg/day | 16 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 8000.0 | mg/day | 8 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 160.0 | drops/knee/day | 160 | drops/knee/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
| Max dose for adults | 2.0 | patches/day | 2 | patches/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 150.0 | mg/day | 150 | mg/day | intravenous injection, IV | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 200.0 | mg/day | 200 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 150.0 | mg/day | 150 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 125.0 | mg/day | 125 | mg/day | PO, oral | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 32000.0 | mg/day | 32 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 16000.0 | mg/day | 16 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 8000.0 | mg/day | 8 | g/day | gel | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 160.0 | drops/knee/day | 160 | drops/knee/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
| Max dose for geriatric | 2.0 | patches/day | 2 | patches/day | skin/dermal | Zipsor | diclofenac potassium | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1